Inicio › Linfoma de Burkitt › Ohio

Ensayos clínicos de Linfoma de Burkitt en Ohio

18 estudios sobre Linfoma de Burkitt buscan participantes en Ohio.

Ciudades en Ohio

Texto oficial del estudio (inglés)

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Cincinnati Children's Hospital, Cincinnati

ReclutandoFase 1

Edades de 0 a 18 · Todos los sexos · Actualizado el 13 nov 2026 · NCT06173518

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Ohio State University Comprehensive Cancer Center, Columbus
University of Cincinnati Cancer Center-West Chester, West Chester

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03739814

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
y 3 más

ReclutandoFase 2

Edades de 1 a 30 · Todos los sexos · Actualizado el 12 nov 2026 · NCT04546399

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Cincinnati Children's Hospital Medical Center, Cincinnati

ReclutandoFase 3

Edades de 1 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07223021

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
Case Western Reserve University, Cleveland
Cleveland Clinic Foundation, Cleveland
y 2 más

ReclutandoFase 3

Edades de 18 a 39 · Todos los sexos · Actualizado el 3 nov 2026 · NCT03150693

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Cincinnati Children's Hospital Medical Center, Cincinnati

ReclutandoEstudio observacional

Edades de 0 a 38 · Todos los sexos · Actualizado el 29 oct 2026 · NCT06131801

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
y 2 más

ReclutandoFase 2

365 Days · Todos los sexos · Actualizado el 27 oct 2026 · NCT06317662

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
y 3 más

ReclutandoFase 2

366 Days – 46 Years · Todos los sexos · Actualizado el 27 oct 2026 · NCT06124157

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

The Ohio State University Wexner Medical Center, Columbus

ReclutandoFase 1/2

Edades de 13 a 90 · Todos los sexos · Actualizado el 26 oct 2026 · NCT06533579

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

University of Cincinnati Medical Center, Cincinnati

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Cleveland Clinic Foundation, Cleveland

ReclutandoFase 2

Edades de 18 a 54 · Todos los sexos · Actualizado el 13 oct 2026 · NCT06918431

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Hospital Medical Center of Akron, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
Rainbow Babies and Childrens Hospital, Cleveland
y 4 más

ReclutandoFase 3

365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Cincinnati Children's Hospital Medical Center, Cincinnati

ReclutandoFase 2

Edades de 7 a 25 · Todos los sexos · Actualizado el 19 ago 2026 · NCT05082519

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Nationwide Children's Hospital, Columbus
Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoFase 1

Edades de 2 en adelante · Todos los sexos · Actualizado el 29 may 2026 · NCT05418088

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Cincinnati Children's Hospital Medical Center, Cincinnati

ReclutandoFase 1

Edades de 1 a 39 · Todos los sexos · Actualizado el 18 feb 2026 · NCT06863259

Study of SGR-1505 in Mature B-Cell Neoplasms

Gabrail Cancer & Research Center, Canton
The Ohio State University - The James Cancer Hospital, Columbus

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Cleveland Clinic, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2025 · NCT04260022

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

University of Cincinnati, Cincinnati

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 nov 2024 · NCT06034275

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.